mhurhangee/ep-ind-claims huggingface dataset:
A method of manufacturing a chorionic membrane product comprising the steps of: a. selectively depleting the chorionic membrane of a placenta of one or more types of viable immunogenic cells, wherein i. the one or more types of immunogenic cells comprise functional CD14+ macrophages, ii. the step of selective depletion does not comprise killing or removing native therapeutic cells selected from MSCs, fibroblasts, and a combination thereof, iii the selective depletion is a substantial amount of at least 50% compared to an unprocessed membrane, iv the step of selective depletion comprises incubating the chorionic membrane, with all or a portion of the trophoblast layer removed, in a cryopreservation medium at a temperature above freezing for at least 30 minutes; followed directly by b. cryopreserving the chorionic membrane in the cryopreservation medium, wherein the cryopreserved chorionic membrane comprises at least 70% viable therapeutic cells, thereby providing a chorionic membrane selectively depleted of at least 50% of one or more types of viable immunogenic cells, wherein the chorionic membrane comprises viable therapeutic cells, wherein the viable therapeutic cells are native to the chorionic membrane, and wherein the viable cells comprise MSCs, and fibroblasts. a. selectively depleting the chorionic membrane of a placenta of one or more types of viable immunogenic cells, wherein i. the one or more types of immunogenic cells comprise functional CD14+ macrophages, ii. the step of selective depletion does not comprise killing or removing native therapeutic cells selected from MSCs, fibroblasts, and a combination thereof, iii the selective depletion is a substantial amount of at least 50% compared to an unprocessed membrane, iv the step of selective depletion comprises incubating the chorionic membrane, with all or a portion of the trophoblast layer removed, in a cryopreservation medium at a temperature above freezing for at least 30 minutes; followed directly by i. the one or more types of immunogenic cells comprise functional CD14+ macrophages, ii. the step of selective depletion does not comprise killing or removing native therapeutic cells selected from MSCs, fibroblasts, and a combination thereof, iii the selective depletion is a substantial amount of at least 50% compared to an unprocessed membrane, iv the step of selective depletion comprises incubating the chorionic membrane, with all or a portion of the trophoblast layer removed, in a cryopreservation medium at a temperature above freezing for at least 30 minutes; followed directly by b. cryopreserving the chorionic membrane in the cryopreservation medium, wherein the cryopreserved chorionic membrane comprises at least 70% viable therapeutic cells,
A table for compensating deformation in flexible foils, comprising - a supportive base; and - a deformation compensation system, the deformation compensation system comprising a plurality of movable elements supported by said base; the movable elements forming a surface for supporting the flexible foil; the movable elements comprising clamps for clamping the foil, characterized in that - the movable elements are individually movable parallel to the surface for supporting the foil, so as to stretch the clamped foil into a predefined shape. - a supportive base; and - a deformation compensation system, the deformation compensation system comprising a plurality of movable elements supported by said base; the movable elements forming a surface for supporting the flexible foil; the movable elements comprising clamps for clamping the foil, characterized in that - the movable elements are individually movable parallel to the surface for supporting the foil, so as to stretch the clamped foil into a predefined shape.
A process to prepare an olefin polymerization procatalyst comprising a Ti 3+ complex, said process comprising: a) forming a delta form MgCl 2 species by combining i) R 2 Mg in a solvent selected from C 5-12 alkanes, and ii) reactive organic chloride or HCl; wherein each R is independently selected from C 2-8 alkyl radicals, and wherein the mole ratio of added Cl and Mg is from about 2.0 to about 3.0; b) adding to said delta form MgCl 2 species prepared in step a) R 1 x AlX 3-x and a tetravalent titanium compound in any order or at the same time, wherein the Al/Ti molar ratio is from about 3 to about 10; or c) adding to said delta form MgCl 2 species prepared in step a), an aluminum alkyl halide of the formula R 1 x AlX 3-x first, a tetravalent titanium compound second, followed by an alkyl aluminum alkoxide of the formula R 4 y AlOR 5 3-y, wherein the Al/Ti molar ratio when measuring Al supplied from R 1 x AlX 3-x only is from about 0.7 to about 2 and the Al/Ti molar ratio when measuring Al supplied from R 4 y AlOR 5 3-y is from about 1 to about 2; and further wherein the Mg/Ti molar ratio is from about 5 to about 10; x is 1 or 2; y is 1 or 2; each R 1 is independently selected from C 1-8 alkyl radicals; the tetravalent titanium compound is selected from TiR 2 X 3, Ti(OR 3)X 3, TiX 4, and mixtures thereof; each X is independently selected from the halogen radicals; and each R 2 is independently selected from C 1-8 alkyl radicals and benzyl. each R 3, R 4 and R 5 are independently selected from C 1-8 alkyl radicals. a) forming a delta form MgCl 2 species by combining i) R 2 Mg in a solvent selected from C 5-12 alkanes, and ii) reactive organic chloride or HCl; wherein each R is independently selected from C 2-8 alkyl radicals, and wherein the mole ratio of added Cl and Mg is from about 2.0 to about 3.0; i) R 2 Mg in a solvent selected from C 5-12 alkanes, and ii) reactive organic chloride or HCl; wherein each R is independently selected from C 2-8 alkyl radicals, and wherein the mole ratio of added Cl and Mg is from about 2.0 to about 3.0; b) adding to said delta form MgCl 2 species prepared in step a) R 1 x AlX 3-x and a tetravalent titanium compound in any order or at the same time, wherein the Al/Ti molar ratio is from about 3 to about 10; or c) adding to said delta form MgCl 2 species prepared in step a), an aluminum alkyl halide of the formula R 1 x AlX 3-x first, a tetravalent titanium compound second, followed by an alkyl aluminum alkoxide of the formula R 4 y AlOR 5 3-y, wherein the Al/Ti molar ratio when measuring Al supplied from R 1 x AlX 3-x only is from about 0.7 to about 2 and the Al/Ti molar ratio when measuring Al supplied from R 4 y AlOR 5 3-y is from about 1 to about 2; the Mg/Ti molar ratio is from about 5 to about 10; x is 1 or 2; y is 1 or 2; each R 1 is independently selected from C 1-8 alkyl radicals; the tetravalent titanium compound is selected from TiR 2 X 3, Ti(OR 3)X 3, TiX 4, and mixtures thereof; each X is independently selected from the halogen radicals; and each R 2 is independently selected from C 1-8 alkyl radicals and benzyl. each R 3, R 4 and R 5 are independently selected from C 1-8 alkyl radicals.
Method for preparing a stable alcoholic drink with a pH in the range from 5.2 to 6.5, comprising one or more milk and/or soy proteins, alcohol and one or more stabilizers, which method comprises the following steps: a) mixing at least a portion of the milk and/or soy proteins and at least a portion of the stabilizers in an aqueous medium to obtain a mixture; b) setting the pH of the mixture to 3.5-4.5; c) homogenizing the mixture obtained in step b) to obtain a homogenate; d) setting the pH of the homogenate to 5.2-6.5; e) mixing in the alcohol and optionally a residual portion of the milk and/or soy proteins and of the stabilizers during or after one or more of steps a)-d). a) mixing at least a portion of the milk and/or soy proteins and at least a portion of the stabilizers in an aqueous medium to obtain a mixture; b) setting the pH of the mixture to 3.5-4.5; c) homogenizing the mixture obtained in step b) to obtain a homogenate; d) setting the pH of the homogenate to 5.2-6.5; e) mixing in the alcohol and optionally a residual portion of the milk and/or soy proteins and of the stabilizers during or after one or more of steps a)-d).
A linear compressor comprising: a shell to which a suction pipe is coupled; a cylinder disposed inside the shell to define a compression space; a piston reciprocating inside the cylinder to compress a refrigerant in the compression space; and a muffler through which the refrigerant suctioned through the suction pipe flows to and is provided to the compression space, wherein the muffler includes: a plurality of flow tubes (212, 222, 240) extending in the axial direction of the piston; and a plurality of through-holes (242, 228) passing through at least one of the plurality of flow tubes, wherein the muffler comprises a first muffler; and a second muffler coupled to a rear portion of the first muffler, characterized in that the muffler further comprises: a third muffler in which the second muffler is accommodated and which is coupled to a rear portion of the piston; and a perforated tube which is disposed between the first muffler and the second muffler and in which the plurality of through-holes are formed. a shell to which a suction pipe is coupled; a cylinder disposed inside the shell to define a compression space; a piston reciprocating inside the cylinder to compress a refrigerant in the compression space; and a muffler through which the refrigerant suctioned through the suction pipe flows to and is provided to the compression space, wherein the muffler includes: a plurality of flow tubes (212, 222, 240) extending in the axial direction of the piston; and a plurality of through-holes (242, 228) passing through at least one of the plurality of flow tubes, wherein the muffler comprises a first muffler; and a second muffler coupled to a rear portion of the first muffler, characterized in that the muffler further comprises: a third muffler in which the second muffler is accommodated and which is coupled to a rear portion of the piston; and a perforated tube which is disposed between the first muffler and the second muffler and in which the plurality of through-holes are formed. a plurality of flow tubes (212, 222, 240) extending in the axial direction of the piston; and a plurality of through-holes (242, 228) passing through at least one of the plurality of flow tubes, wherein the muffler comprises a first muffler; and a second muffler coupled to a rear portion of the first muffler, characterized in that the muffler further comprises: a third muffler in which the second muffler is accommodated and which is coupled to a rear portion of the piston; and a perforated tube which is disposed between the first muffler and the second muffler and in which the plurality of through-holes are formed. a third muffler in which the second muffler is accommodated and which is coupled to a rear portion of the piston; and a perforated tube which is disposed between the first muffler and the second muffler and in which the plurality of through-holes are formed.
Apparatus for use in wound therapy of mammals, the apparatus comprising: a dressing covering the wound, the dressing being substantially sealed to prevent free entry and egress of ambient atmospheric air to the wound; aspiration means operably connected to a space between the dressing and the wound by an aspiration conduit sealed to the point of entry between wound and dressing against ingress of ambient atmosphere, said conduit being for aspiration of said wound and for removal of fluid from said space between said wound and said dressing; and a waste container for receiving fluid to be discarded operably connected to said aspiration conduit; wherein the apparatus further comprises heating means for heating said aspirated fluid in order to increase the vapour pressure thereof and to cause evaporation to reduce the volume of the fluid in the waste container, characterized in that the heating means are formed integrally with the waste container and/or as part of the aspiration conduit immediately prior to the entry into the waste container. a dressing covering the wound, the dressing being substantially sealed to prevent free entry and egress of ambient atmospheric air to the wound; aspiration means operably connected to a space between the dressing and the wound by an aspiration conduit sealed to the point of entry between wound and dressing against ingress of ambient atmosphere, said conduit being for aspiration of said wound and for removal of fluid from said space between said wound and said dressing; and a waste container for receiving fluid to be discarded operably connected to said aspiration conduit; wherein the apparatus further comprises heating means for heating said aspirated fluid in order to increase the vapour pressure thereof and to cause evaporation to reduce the volume of the fluid in the waste container, characterized in that the heating means are formed integrally with the waste container and/or as part of the aspiration conduit immediately prior to the entry into the waste container.
A method of transmitting a signal by a first apparatus, the method comprising the steps of: generating a pulse signal including a control signal for controlling a second apparatus and a clock signal for obtaining a synchronization with the second apparatus; and transmitting, to the second apparatus, the pulse signal and a radio frequency, RF, signal for communication with a base station, wherein the clock signal and the control signal are assigned to different time units, and wherein the pulse signal and the RF signal are signals of different frequency bands. generating a pulse signal including a control signal for controlling a second apparatus and a clock signal for obtaining a synchronization with the second apparatus; and transmitting, to the second apparatus, the pulse signal and a radio frequency, RF, signal for communication with a base station, wherein the clock signal and the control signal are assigned to different time units, and wherein the pulse signal and the RF signal are signals of different frequency bands.
A kit for quantitatively determining a bile acid in a biological sample, comprising: a compound represented by General Formula in a dry state; a fluorescent particle that has a first binding substance capable of binding to the bile acid; and a substrate that has a detection region having a second binding substance capable of binding to any one of the bile acid and the first binding substance, in the formula, R represents -NH-C 6 H 5, -NH 2, or -NH-CH 2 -CH 2 -NH 2. a compound represented by General Formula in a dry state; a fluorescent particle that has a first binding substance capable of binding to the bile acid; and a substrate that has a detection region having a second binding substance capable of binding to any one of the bile acid and the first binding substance, in the formula, R represents -NH-C 6 H 5, -NH 2, or -NH-CH 2 -CH 2 -NH 2.
A computer-implemented method for automatically identifying violations in one or more test cases, a test case being a natural language expression and including a violation when the test case does not define a valid test, the method comprising: retrieving the one or more test cases, comprising one or more tokens being a word, a phrase, a symbol, or an abbreviation, from a test case database associated with the test case validation system; assigning a Part-Of-Speech tag to each of the one or more tokens of each of the one or more test cases, a POS tag describing a grammatical and/or syntactical property of a token; categorizing each of the one or more test cases into at least one of a binary test case and an event-based test case based on the POS tag assigned to each of the one or more tokens of each of the one or more test cases, wherein the event-based test cases are the test cases that comprise a subject, an object and a condition, wherein the binary test cases are the test cases that comprise the subject and the object; detecting a POS pattern of each of the one or more test cases based on one or more predefined rules; comparing at least one of the POS pattern of each of the one or more test cases and the one or more tokens of each of the one or more test cases with at least one of predefined POS patterns and predefined tokens, wherein the predefined POS patterns and the predefined tokens used for the comparison are based on the categorization of each of the one or more test cases; and identifying a violation in the one or more test cases based on the comparison. retrieving the one or more test cases, comprising one or more tokens being a word, a phrase, a symbol, or an abbreviation, from a test case database associated with the test case validation system; assigning a Part-Of-Speech tag to each of the one or more tokens of each of the one or more test cases, a POS tag describing a grammatical and/or syntactical property of a token; categorizing each of the one or more test cases into at least one of a binary test case and an event-based test case based on the POS tag assigned to each of the one or more tokens of each of the one or more test cases, wherein the event-based test cases are the test cases that comprise a subject, an object and a condition, wherein the binary test cases are the test cases that comprise the subject and the object; detecting a POS pattern of each of the one or more test cases based on one or more predefined rules; comparing at least one of the POS pattern of each of the one or more test cases and the one or more tokens of each of the one or more test cases with at least one of predefined POS patterns and predefined tokens, wherein the predefined POS patterns and the predefined tokens used for the comparison are based on the categorization of each of the one or more test cases; and identifying a violation in the one or more test cases based on the comparison.
A downhole tool (30, 100) for use with a deployed plug, comprising: a mandrel (50, 150) defining an inner bore (54, 154) with an inner port (56, 156), the inner port (56, 156) communicating fluid pressure in the inner bore (54, 154) with an inner space (58, 158) in the tool (30, 100); a seat (80, 180) rotatably disposed in the inner bore (54, 154) of the mandrel (50, 150) and defining an interior passage therethrough, the interior passage having a seat profile for engaging the deployed plug; and a first piston (60a, 160a) connected to the seat (80, 180) and movable in the inner space (58, 158) of the tool (30, 100) in response to the communicated fluid pressure, the first piston (60a, 160a) moved in a first direction rotating the seat (80, 180) in a first rotation to a first orientation, the seat (80, 180) in the first orientation configured to engage the deployed plug, the first piston (60a, 160a) moved in a second direction rotating the seat (80, 180) in a second rotation to a second orientation, the seat (80, 180) in the second orientation configured to release the deployed plug. a mandrel (50, 150) defining an inner bore (54, 154) with an inner port (56, 156), the inner port (56, 156) communicating fluid pressure in the inner bore (54, 154) with an inner space (58, 158) in the tool (30, 100); a seat (80, 180) rotatably disposed in the inner bore (54, 154) of the mandrel (50, 150) and defining an interior passage therethrough, the interior passage having a seat profile for engaging the deployed plug; and a first piston (60a, 160a) connected to the seat (80, 180) and movable in the inner space (58, 158) of the tool (30, 100) in response to the communicated fluid pressure, the first piston (60a, 160a) moved in a first direction rotating the seat (80, 180) in a first rotation to a first orientation, the seat (80, 180) in the first orientation configured to engage the deployed plug, the first piston (60a, 160a) moved in a second direction rotating the seat (80, 180) in a second rotation to a second orientation, the seat (80, 180) in the second orientation configured to release the deployed plug.
Lateral flow immunoassay for the detection of anti-drug antibodies against a biological drug comprising: a membrane comprising: - a capture area; - a sample application area; - a flow path from the sample application area to the capture area; and - a conjugate area located in the flow path, characterized in that the conjugate area comprises said biological drug detectably labeled and the capture area comprises said biological drug immobilized thereto. - a capture area; - a sample application area; - a flow path from the sample application area to the capture area; and - a conjugate area located in the flow path, characterized in that the conjugate area comprises said biological drug detectably labeled and the capture area comprises said biological drug immobilized thereto.
A liposome comprising a pHLIP polypeptide, wherein a hydrophobic region of the lipid bilayer of said liposome is substantially free of said pHLIP polypeptide, and wherein (a) said pHLIP polypeptide is directly attached to the headgroup of a phospholipid in said lipid bilayer; or (b) a polymer is attached to the headgroup of a phospholipid of said lipid bilayer and said pHLIP polypeptide is directly attached to said polymer. (a) said pHLIP polypeptide is directly attached to the headgroup of a phospholipid in said lipid bilayer; or (b) a polymer is attached to the headgroup of a phospholipid of said lipid bilayer and said pHLIP polypeptide is directly attached to said polymer.
An apparatus for assessing degradation and estimating strength by using ultrasound, the apparatus comprising: an ultrasound transmitting unit making an ultrasound signal having a single frequency be incident in an inspected object; an ultrasound receiving unit receiving the ultrasound signal penetrating the inspected object or reflected on the inspected object; a signal processing unit calculating a propagation speed through a time interval of the ultrasound signal received by the ultrasound receiving unit and separates the received ultrasound signal into a fundamental frequency component and a harmonic component to calculate non-linear parameter, and measuring linear and non-linear elastic coefficients by using the propagation speed and the non-linear parameter; and a strength estimating unit obtaining a tensile curve by using the linear and non-linear elastic coefficients and estimating at least one of tensile strength and yield strength by using the tensile curve. an ultrasound transmitting unit making an ultrasound signal having a single frequency be incident in an inspected object; an ultrasound receiving unit receiving the ultrasound signal penetrating the inspected object or reflected on the inspected object; a signal processing unit calculating a propagation speed through a time interval of the ultrasound signal received by the ultrasound receiving unit and separates the received ultrasound signal into a fundamental frequency component and a harmonic component to calculate non-linear parameter, and measuring linear and non-linear elastic coefficients by using the propagation speed and the non-linear parameter; and a strength estimating unit obtaining a tensile curve by using the linear and non-linear elastic coefficients and estimating at least one of tensile strength and yield strength by using the tensile curve.